Somatic B-Cell Gene Vaccination with Anti-DNA Ig Consensus Peptide Protects (NZB × NZW) F1 Lupus Mice From Renal Disease

Recently we have identified subgroups of de novo primary diffuse large B-cell lymphoma (DLBCL) based on complementary DNA microarray-generated gene expression profiles. To correlate the gene expression profiles with cytogenetic abnormalities in these DLBCLs, we examined the occurrence of the t(14;18)(q32;q21) in the 2 distinctive subgroups of DLBCL: one with the germinal center B-cell gene expression signature and the other with the activated B cell–like gene expression signature. The t(14;18) was detected in 7 of 35 cases (20%). All 7 t(14;18)-positive cases had a germinal center B-cell gene expression profile, representing 35% of the cases in this subgroup, and 6 of these 7 cases had very similar gene expression profiles. The expression of bcl-2 and bcl-6 proteins was not significantly different between the t(14;18)-positive and -negative cases, whereas CD10 was detected only in the group with the germinal center B-cell expression profile, and CD10 was most frequently expressed in the t(14;18)-positive cases. This study supports the validity of subdividing DLBCL into 2 major subgroups by gene expression profiling, with the t(14;18) being an important event in the pathogenesis of a subset of DLBCL arising from germinal center B cells. CD10 protein expression is useful in identifying cases of DLBCL with a germinal center B-cell gene expression profile and is often expressed in cases with the t(14;18).

Download Full-text

The Complexity and Heterogeneity of Monoclonal Immunoglobulin–Associated Renal Diseases

Journal of the American Society of Nephrology ◽

10.1681/asn.2017121319 ◽

2018 ◽

Vol 29 (7) ◽

pp. 1810-1823 ◽

Cited By ~ 45

Author(s):

Sanjeev Sethi ◽

S. Vincent Rajkumar ◽

Vivette D. D’Agati

Keyword(s):

Renal Disease ◽

B Cell ◽

B Lymphocytes ◽

Plasma Cells ◽

Hematologic Malignancy ◽

Organ Damage ◽

Renal Tissue ◽

Renal Diseases ◽

Malignant Neoplasms ◽

Cast Nephropathy

Monoclonal gammopathies are characterized by the overproduction of monoclonal Ig (MIg) detectable in the serum or urine resulting from a clonal proliferation of plasma cells or B lymphocytes. The underlying hematologic conditions range from malignant neoplasms of plasma cells or B lymphocytes, including multiple myeloma and B-cell lymphoproliferative disorders, to nonmalignant small clonal proliferations. The term MGUS implies presence of an MIg in the setting of a “benign” hematologic condition without renal or other end organ damage. The term MGRS was recently introduced to indicate monoclonal gammopathy with MIg-associated renal disease in the absence of hematologic malignancy. Most MIg-associated renal diseases result from the direct deposition of nephrotoxic MIg or its light- or heavy-chain fragments in various renal tissue compartments. Immunofluorescence microscopy is essential to identify the offending MIg and define its tissue distribution. Mass spectrometry is helpful in difficult cases. Conditions caused by direct tissue deposition of MIg include common disorders, such as cast nephropathy, amyloidosis, and MIg deposition diseases, as well as uncommon disorders, such as immunotactoid glomerulopathy, proliferative GN with MIg deposits, light-chain proximal tubulopathy, and the rare entities of crystal-storing histiocytosis and crystalglobulinemia. Indirect mechanisms of MIg-induced renal disease can cause C3 glomerulopathy or thrombotic microangiopathy without tissue MIg deposits. Treatment of MIg-associated renal disease is aimed at eliminating the clonal plasma cell or B-cell population as appropriate. Both the renal and the underlying hematologic disorders influence the management and prognosis of MIg-associated renal diseases.

Download Full-text

Profiles of B-cell subsets in immunologically stable renal allograft recipients and end-stage renal disease patients

Transplant Immunology ◽

10.1016/j.trim.2019.101249 ◽

2020 ◽

Vol 58 ◽

pp. 101249

Author(s):

Quan Zhuang ◽

Hao Li ◽

Meng Yu ◽

Bo Peng ◽

Shu Liu ◽

...

Keyword(s):

Renal Disease ◽

B Cell ◽

End Stage Renal Disease ◽

Renal Allograft ◽

B Cell Subsets ◽

Stage Renal Disease ◽

End Stage

Download Full-text

Hoxa9 collaborates with E2A-PBX1 in mouse B cell leukemia in association with Flt3 activation and decrease of B cell gene expression

Developmental Dynamics ◽

10.1002/dvdy.24056 ◽

2013 ◽

Vol 243 (1) ◽

pp. 145-158 ◽

Cited By ~ 7

Author(s):

Mona Hassawi ◽

Elena A. Shestakova ◽

Marilaine Fournier ◽

Charles-Étienne Lebert-Ghali ◽

Gratianne Vaisson ◽

...

Keyword(s):

Gene Expression ◽

B Cell ◽

Cell Leukemia ◽

Cell Gene Expression ◽

B Cell Leukemia ◽

Cell Gene

Download Full-text

A B-Cell Gene Signature Correlates With the Extent of Gluten-Induced Intestinal Injury in Celiac Disease

Cellular and Molecular Gastroenterology and Hepatology ◽

10.1016/j.jcmgh.2017.01.011 ◽

2017 ◽

Vol 4 (1) ◽

pp. 1-17 ◽

Cited By ~ 7

Author(s):

Mitchell E. Garber ◽

Alok Saldanha ◽

Joel S. Parker ◽

Wendell D. Jones ◽

Katri Kaukinen ◽

...

Keyword(s):

Celiac Disease ◽

B Cell ◽

Gene Signature ◽

Intestinal Injury ◽

Cell Gene

Download Full-text

P0273THE EFFECT OF END STAGE RENAL DISEASE AND RENAL REPLACEMENT THERAPY ON B LYMPHOCYTE SUBPOPULATIONS

Nephrology Dialysis Transplantation ◽

10.1093/ndt/gfaa142.p0273 ◽

2020 ◽

Vol 35 (Supplement_3) ◽

Author(s):

Dimitra Vasileia Daikidou ◽

MARIA STANGOU ◽

Erasmia Sampani ◽

Vasiliki Nikolaidou ◽

Despoina Asouchidou ◽

...

Keyword(s):

B Cells ◽

Renal Replacement Therapy ◽

Renal Disease ◽

B Cell ◽

Replacement Therapy ◽

End Stage Renal Disease ◽

Stage Renal Disease ◽

End Stage ◽

The Impact ◽

Esrd Patients

Abstract Background and Aims End-stage renal disease (ESRD) is linked to immunodeficiency, which makes a significant contribution to morbidity and mortality. Disturbances in innate and adaptive immunity have been described in patients on dialysis, although their association with the therapy itself is yet to be defined. The present study aimed to assess the impact of dialysis on B cell subpopulations Method B cells (CD19+) and their subsets B1a (CD19+CD5+), naive (CD19+CD27−), memory (CD19+CD27+), (CD19+BAFFR+) and (CD19+IgM+), were quantified using flow-cytometry of in the peripheral blood of ESRD patients, the first day on dialysis (T0), and repeated 6 months later (T6). The results were compared to age-matched healthy control group. Exclusion criteria were age <18 or>75 years, active autoimmune or chronic inflammatory disease, medical history of malignancy, corticosteroids or immunosuppresive treatment for the last 12 months Results Pre dialysis ESRD patients had reduced lymphocyte count (1527±646μ/L vs. 2459±520μ/L, p<0.001) and B cell (CD19+) count (82.7±59.5μ/L vs. 177.6±73.8μ/L, p<0.001) compared to controls, whereas the percentages of B cell subsets were not particularly affected, except for B1a subset which presented a significant increase (4.1±3.6% vs. 0.7±0.7% p<0.001). In 17 patients who had a follow-up sample 6 months later, the percentage of most subsets was reduced (CD19+CD5+: 1.02±0.8% from 3.6±4.6%, p=0.015, Naive: 40±22.3% from 61±17.4%, p=0.001, CD19+BAFF+:75.8±12.6% from 82.1±9.1%, p=0.04,), apart from memory B cells percentage, which was increased (49.4±52.1% from 32,9±35,5%, p=0.01) and CD19+ IgM+ percentage, which was unaffected . Conclusion A significant reduction of almost all subsets of B cells was noticed in patients with ESRD on pre-dialysis stage. Furthermore, the initiation of renal replacement therapy may be linked to further alterations in B cells subpopulations, especially at their early stages.

Download Full-text